| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Ergosterol peroxide glucoside targets inflammatory pathways, exhibiting anti-inflammatory activity. As a sterol glycoside, it may interact with cell membranes and modulate signaling pathways. Ergosterol peroxide, the aglycone, exhibits anti-cancer, amoebicidal, anticomplementary, antibacterial, antiviral, antioxidant, and anti-melanogenic activities, suggesting that the glucoside may share some of these activities.
|
|---|---|
| ln Vitro |
In vitro, Ergosterol peroxide glucoside exhibits anti-inflammatory activity. The compound is an ergosterol analogue. Ergosterol peroxide, the related compound, exhibits anti-cancer, amoebicidal, anticomplementary, antibacterial, antiviral, antioxidant, and anti-melanogenic activities.
|
| ln Vivo |
In vivo activity data for Ergosterol peroxide glucoside are limited. The compound is a natural product found in mushrooms. Its anti-inflammatory activity has been reported, but specific animal model studies have not been detailed.
|
| Enzyme Assay |
Specific protocols for enzyme or receptor binding assays have not been established for Ergosterol peroxide glucoside. Anti-inflammatory activity can be assessed using assays that measure the production of pro-inflammatory cytokines in activated immune cells. Binding studies may involve assessing interactions with cell membrane components.
|
| Cell Assay |
Cell-based assays for Ergosterol peroxide glucoside may include evaluating its anti-inflammatory effects in macrophage cell lines by measuring cytokine production. Cytotoxicity can be assessed using standard viability assays. The compound's effects on melanogenesis may be evaluated in melanoma cell lines.
|
| Animal Protocol |
In vivo animal protocols for Ergosterol peroxide glucoside have not been established. For related sterol glycosides with anti-inflammatory activity, standard models involve administering the compound to rodents and measuring inflammatory markers. Specific protocols for this compound are not documented.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Ergosterol peroxide glucoside are not extensively reported. The compound has a molecular weight of 590.79 and a molecular formula of C34H54O8. It appears as a solid at room temperature. As a glycoside, it may be hydrolyzed by intestinal enzymes. Storage follows standard conditions for natural products.
|
| Toxicity/Toxicokinetics |
Toxicological data for Ergosterol peroxide glucoside are limited. As a natural product from mushrooms, it is generally considered to have low toxicity, but formal safety assessments are lacking. The peroxide bridge may confer additional reactivity. Standard laboratory precautions should be observed.
|
| References | |
| Additional Infomation |
3-O-β-D-glucopyranosyl-22E,24R-5α,8α-epoxyergosterol-6,22-diene is a steroidal saponin. Ergosterol peroxide glucoside has been reported in Sarcodon scabrosus, Hydnellum scabrosum, and Hypholoma fasciculare, but relevant data are limited.
Ergosterol peroxide glucoside is a research-use-only compound. It is a naturally occurring sterol glycoside found in mushrooms such as Lactarius volemus. It exhibits anti-inflammatory activity. The related compound ergosterol peroxide exhibits anti-cancer, amoebicidal, anticomplementary, antibacterial, antiviral, antioxidant, and anti-melanogenic activities. It is used in natural product research. |
| Molecular Formula |
C34H54O8
|
|---|---|
| Molecular Weight |
590.7878
|
| Exact Mass |
590.381
|
| CAS # |
140447-22-9
|
| PubChem CID |
10745980
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
675.9±55.0 °C at 760 mmHg
|
| Flash Point |
362.6±31.5 °C
|
| Vapour Pressure |
0.0±4.7 mmHg at 25°C
|
| Index of Refraction |
1.582
|
| LogP |
5.73
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
42
|
| Complexity |
1060
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
O1[C@]23C([H])=C([H])[C@]4(C([H])([H])C([H])(C([H])([H])C([H])([H])[C@]4(C([H])([H])[H])C2([H])C([H])([H])C([H])([H])[C@]2(C([H])([H])[H])C([H])(C([H])(C([H])=C([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])C32[H])OC2([H])C([H])(C([H])(C([H])(C([H])(C([H])([H])O[H])O2)O[H])O[H])O[H])O1
|
| InChi Key |
CKJZKFPVVUQBMB-AGBBTXFXSA-N
|
| InChi Code |
InChI=1S/C34H54O8/c1-19(2)20(3)7-8-21(4)23-9-10-25-31(23,5)13-12-26-32(6)14-11-22(17-33(32)15-16-34(25,26)42-41-33)39-30-29(38)28(37)27(36)24(18-35)40-30/h7-8,15-16,19-30,35-38H,9-14,17-18H2,1-6H3/b8-7+/t20-,21+,22-,23+,24+,25+,26+,27+,28-,29+,30+,31+,32+,33+,34-/m0/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(1S,2R,5R,6R,9R,10R,13S,15S)-5-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-6,10-dimethyl-16,17-dioxapentacyclo[13.2.2.01,9.02,6.010,15]nonadec-18-en-13-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6926 mL | 8.4632 mL | 16.9265 mL | |
| 5 mM | 0.3385 mL | 1.6926 mL | 3.3853 mL | |
| 10 mM | 0.1693 mL | 0.8463 mL | 1.6926 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
